Revenue: As of FY2025 Q2, the actual value is USD 3.149 B.EPS: As of FY2025 Q2, the actual value is USD 0.13.EBIT: As of FY2025 Q2, the actual value is USD 90.4 M.<h3>Segment Revenue</h3><ul><li>Pharmacy Solutions Revenue: $2,790 million, up 32% from $2,114 million in Q2 2024.</li><li>Provider Services Revenue: $358 million, up 11% from $324 million in Q2 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income from Continuing Operations: $8.5 million, unchanged from Q2 2024.</li><li>Gross Profit: $375 million, up 20.1% from $312 million in Q2 2024.</li><li>Operating Income: $48.6 million, up from $38.7 million in Q2 2024.</li><li>Adjusted EBITDA: $143 million, up 28.8% from $111 million in Q2 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $49.1 million, compared to - $15.2 million in Q2 2024.</li><li>Net Cash Used in Investing Activities: - $23.2 million, compared to - $57.7 million in Q2 2024.</li><li>Net Cash Used in Financing Activities: - $8.2 million, compared to $39.9 million in Q2 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Total Segment Adjusted EBITDA: $181 million, up 25% from $145 million in Q2 2024.</li></ul><h3>Outlook / Guidance</h3>BrightSpring Health Services has increased its full-year 2025 guidance, projecting net revenue between $12,200 million and $12,600 million, representing growth of 21.1% to 25.1% compared to 2024. Adjusted EBITDA is expected to be between $590 million and $605 million, reflecting growth of 28.2% to 31.5%.

BrightSpring Health Services - Unit | 8-K: FY2025 Q2 Revenue: USD 3.149 B